Mraz Lab
@MrazLab
Marek Mraz research group
Our new paper describes a non-genetic adaptation mechanism to BTK inhibitor therapy in CLL. CLL cells have a compensatory AKT activation during therapy that helps them to survive, and this is driven by the BTK-independent activity of the FOXO1-Rictor axis.
Shaping the future of European #healthresearch: in this new article, BioMed Alliance presents #policy recommendations for Framework Programme 10 and beyond ➡️ tinyurl.com/yuy563uy @biomedalliance @tomhemmingk @euforea @MrazLab @CarolRemme biomedeurope.org
#Hematology Single-cell transcriptional mapping reveals genetic and non-genetic determinants of aberrant differentiation in #AML biorxiv.org/content/10.110… #leusm
hu.MAP3.0 >25k #Proteomics experiments >15k human protein complexes covering ~70% human proteins🤠 humap3.proteincomplexes.org Will MYH11-ZFAND5 interaction curb #SmoothMuscleCell Phenotypic degeneration & Ferroptosis be a productive hypothesis?😁 #MolSystBiol 2025…
Phosphoinositide 3-kinase gamma, the only class IB PI3 kinase, is a cell-extrinsic immunotherapy target in solid tumors. ow.ly/wsQF50We38I #myeloidneoplasia
Breaking: Big news for smoldering myeloma. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a new indication for DARZALEX®(daratumumab) subcutaneous (SC) formulation as monotherapy for the treatment…
Big news: Mosun-Pola is superior to chemotherapy for patients with aggressive lymphoma. At @icmlugano, I was honored to present—on behalf of an incredible team of global coauthors—the SUNMO trial: ➡️ First positive Phase III trial in this space without conventional chemotherapy
Very proud of my PhD student Daniel Filip for giving a talk at ICML and EHA conferences
Energy metabolism is really quite remarkable Little bits of energy we call metabolites flow continuously, converging in our mitochondria (TCA or Krebs cycle) where they are re-routed and directed where needed The basis of life and health is the flow of energy Great animation…
CH analysis of a unique and uniform cohort of exclusively healthy individuals exposed to a novel type of selection pressure was conducted. ow.ly/b44S50VXljX #hematopoiesisandstemcells #transfusionmedicine
🚨 Abstracts Due 30 May for #iwCLL2025 🚨 Is your research advancing the science behind the pathogenesis and/or treatment of #CLL or #SLL? Showcase your work in Kraków, Poland! Learn more: loom.ly/Veot8pA
Dr Stephen Ansell to give the “Wiedermannova přednáška” lecture at XXXVII Olomoucké Hematologické Dny 2025 about “Breaking the limits: changing the treatment landscape for #elderly patients with #lymphoma”. Always an honor to learn from him #lymsm #geriheme #hematology
Very proud of our student Laura Ondrisova receiving the award from the Learned Society of the Czech Rep: ceitec.eu/laura-ondrisov…
Laura explainig non-genetix adaptation to targeted therapy in leukemia
Today's Sip of Science: A cartoon-style take on cancer—science meets storytelling! Don't miss this fascinating talk. #ScienceCommunication #CancerResearch @MrazLab 🥼👌
ARGONAUTES 2025 - argonautes.img.cas.cz The meeting of Argonaute afficionados lives on! The registration for #Argonautes2025 is open. Join us in Prague 27-30/8/2025. #miRNA, #siRNA, #piRNA & #PIWI Please, spread the word @Argonautes_conf, @RNASociety, @RNA_ISR, @TorontoRNA
Prof. Jiří Šponer přednesl svou přednášku na konferenci řešitelů Akademické prémie AV ČR. Přednášku najdete na: youtube.com/live/86lgoiRDp… Přednáška začíná v 3. hodině 8. minutě.
CNS relapse rate in HGBCL-DH-BCL2 (6.8% at 2 years) is much lower than previously reported and is associated with clinical risk factors. ow.ly/L2q950UVnrf #clinicaltrialsandobservations #lymphoidneoplasia
🩸✌️Prof. M. Mráz: "Podařilo se nám prokázat, že přibližně u 70 procent pacientů s CLL dochází při léčbě ibrutinibem v leukemických buňkách ke spuštění alternativní signální dráhy vedoucí k aktivaci kinázy Akt." 👉 tribune.cz/vsechny-clanky… @MrazLab @CEITEC_Brno @Science_MEDMUNI
